Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?

Raffaelli, Marco; Sessa, Luca; Mingrone, Geltrude; Bellantone, Rocco
June 2015
Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Jun2015, Vol. 8, p255
Academic Journal
The worldwide prevalence of type 2 diabetes is rising in association with an increasing frequency of overweight and obesity. Bariatric-metabolic procedures are considered as additional therapeutic options, allowing improved diabetes control in most patients. Multiple factors play in concert to achieve the improvements in diabetic remission observed after bariatric-metabolic surgery. Several studies have demonstrated that bariatric-metabolic surgery is an effective treatment for type 2 diabetes when compared with conventional nonsurgical medical treatment. Because the best results are achievable in patients with a relatively short history of diabetes and less advanced controlled disease, the surgical option could be considered early, especially in morbid obese subjects (BMI ≥35 kg/m2) after failure of medical treatment. Patients with extensive weight loss are more likely to achieve type 2 diabetes remission after bariatric surgery. At present, Roux-en-Y gastric bypass seems the surgical procedure of choice because it has fewer risks than biliopancreatic diversion, and it is associated with higher weight loss and metabolic improvements compared with adjustable gastric banding. Recent evidences regarding the effectiveness of sleeve gastrectomy in diabetes remission have to be confirmed by controlled trials with longer follow-up.


Related Articles

  • Long-term Follow-up After Bariatric Surgery. Puzziferri, Nancy; Roshek III, Thomas B.; Mayo, Helen G.; Gallagher, Ryan; Belle, Steven H.; Livingston, Edward H. // JAMA: Journal of the American Medical Association;9/3/2014, Vol. 312 Issue 9, p934 

    IMPORTANCE Bariatric surgery is an accepted treatment for obesity. Despite extensive literature, few studies report long-term follow-up in cohorts with adequate retention rates. OBJECTIVE To assess the quality of evidence and treatment effectiveness 2 years after bariatric procedures for weight...

  • Impact of Different Criteria on Type 2 Diabetes Remission Rate After Bariatric Surgery. Mas-Lorenzo, A.; Benaiges, D.; Flores-Le-Roux, J.; Pedro-Botet, J.; Ramon, J.; Parri, A.; Villatoro, M.; Chillarón, J.; Pera, M.; Grande, L.; Goday, A. // Obesity Surgery;Nov2014, Vol. 24 Issue 11, p1881 

    Background: Laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB) achieve similar type 2 diabetes mellitus (T2DM) remission rates. Since a great variability exists in defining T2DM remission, an expert panel proposed partial and complete remission criteria that...

  • Effects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes. Kelley, David E.; Kuller, Lewis H.; McKolanis, Therese M.; Harper, Patricia; Mancino, Juliet; Kalhan, Satish // Diabetes Care;Jan2004, Vol. 27 Issue 1, p33 

    OBJECTIVE — Moderate weight loss is recommended for overweight and obese patients with type 2 diabetes, and conjunctive use of weight loss medication has been advocated. The current study examined weight loss-dependent and -independent effects of the intestinal lipase inhibitor orlistat...

  • Impact of Different Bariatric Surgical Procedures on Insulin Action and β-Cell Function in Type 2 Diabetes. Ferrannini, Ele; Mingrone, Geltrude // Diabetes Care;Mar2009, Vol. 32 Issue 3, p514 

    The article focuses on the impact of bariatric surgery on insulin action and β-cell function in type 2 diabetes. It mentions a study which indicates a 40% lower mortality among surgical patients in comparison with nonsurgical obese patients. It discusses the effectiveness of bariatric surgery...

  • An intensive lifestyle intervention reduced weight and cardiovascular disease risk factors in overweight and obese people with type 2 diabetes. Chyun, Deborah // Evidence Based Nursing;Jan2008, Vol. 11 Issue 1, p16 

    QUESTION In overweight or obese people with type 2 diabetes, does an intensive lifestyle intervention reduce weight and cardiovascular disease risk factors? METHODS Design: randomised controlled trial (Action for Health in Diabetes [Look AHEAD] trial). Allocation: {concealed}. Blinding: {data...

  • Gastric Electrical Stimulation (TANTALUS-TM) Improves Glycemic Control in Morbidly Obese Patients with Type 2 Diabetes (T2DM). Ludvik, Bernhard; Prager, Gerhard; Weiner, Rudolf; Rosak, Christoph // Diabetes;Jun2007 Supplement 1, Vol. 56, pA164 

    Previous work suggests that non-excitatory electrical stimulation, synchronized to the gastric refractory period and applied during meals, can induce weight loss in morbidly obese subjects. The TANTALUSâ„¢ System (MetaCure N.V.) is a minimally invasive implantable gastric stimulation...

  • Determinants of the Resolution of Type 2 Diabetes After Bariatric Surgery. Zalesin, Kerstyn C.; Krause, Kevin R.; Chengelis, David L.; McCullough, Peter A. // Vascular Disease Prevention;May2008, Vol. 5 Issue 2, p75 

    Background: The association between body mass index (BMI) and the development of type 2 diabetes (T2DM) is well established. The determinants of the resolution of T2DM with weight reduction after bariatric surgery, however, are not fully understood. Objective: Examine the course of T2DM during...

  • XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Torgerson, Jarl S.; Hauptman, Jonathan; Boldrin, Mark N.; Sjöström, Lars // Diabetes Care;Jan2004, Vol. 27 Issue 1, p155 

    OBJECTIVE — It is well established that the risk of developing type 2 diabetes is closely linked to the presence and duration of overweight and obesity. A reduction in the incidence of type 2 diabetes with lifestyle changes has previously been demonstrated. We hypothesized that adding a...

  • Progressive Reduction in Body Weight with Pramlintide Therapy in Obese Subjects with Type 2 Diabetes Treated with Diet and Exercise and/or Metformin. Edelman, Steve; Lush, Cameron; Kesty, Nicole; Burns, Colleen; Weyer, Christian; Frias, Juan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA461 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, has several clinical effects relevant to obesity, including meal-related satiation, reduced food intake, and weight loss. We previously reported that 16-wk PRAM treatment resulted in a placebo (PBO)-corrected change in body weight...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics